Docteur SOPHIE TRIJAU

Publications académiques en France

Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.

• Real-world efficacy and safety of Burosumab in tumor-induced Osteomalacia: case series from an early access program

  2025

  ArticleJBMR Plus

• Absence of overexpression of KIR3DL2 on CD4+ T cells and NK cells in patients with axial spondyloarthritis

  2023

  ArticleRheumatology

• Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study

  2023

  ArticleDigestive and Liver Disease

• COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

  2021

  ArticleThe Lancet Rheumatology

• Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

  2020

  ArticleAnnals of the Rheumatic Diseases

• Frailty in HIV infected people: a new risk factor for bone mineral density loss

  2017

  ArticleAIDS. Official journal of the international AIDS Society

• Bone infarcts: Unsuspected gray areas?

  2016

  ArticleJoint Bone Spine

• Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database.

  2016

  ArticleRMD Open : Rheumatic & Musculoskeletal Diseases

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• APHM HOPITAUX SUD SAINTE MARGUERITE

  249 ET 270 — 270 Boulevard DE SAINTE MARGUERITE, 13274 Marseille 9e Arrondissement

  ☎ 0491380000Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Vidéos & interventions (2)

Source YouTube · recherche par nom (homonymes possibles).

• 41:00

  Dr Sophie TRIJAU Prise en charge de la fragilité osseuse chez les insuffisants chroniques

  COFER · 2 k vues

• 2:11

  3 questions à 1 expert : l'ostéoporose

  AP-HM - Hôpitaux Universitaires de Marseille · 2 k vues

Top publications · les plus citées

• 1

  Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis

  Rheumatology (Oxford, England) · 2010

  📚 42 citations🎯 RCR 1.32
• 2

  Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: a meta-analysis of randomized placebo-controlled trials

  Osteoarthritis and cartilage · 2010

  📚 39 citations🎯 RCR 1.41
• 3

  Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database

  RMD open · 2016

  📚 30 citations🎯 RCR 1.53🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Introduction Long-term glucocorticoid therapy is the leading cause of secondary osteoporosis. The management of glucocorticoid-induced osteoporosis (GIOP) seems to be inadequate in many European countries. Objective To evaluate the rate of screening and treatment of GIOP. Design Information was collected from a national public health-insurance database in our geographic area of Provence-Alpes-Côte-d'Azur and in Corsica, from September 2009 through August 2011. Patients We identified participants aged 15 years and over starting glucocorticoid therapy (≥7.5 mg of prednisone equivalent per day during at least 90 days consecutive). This cohort was compared with an age-matched and sex-matched population that did not receive glucocorticoids. Main outcome measures Bone mass, prescription of bone antiresorptive medication and use of calcium and/or vitamin D treatment. Results We identified 32 812 patients who were prescribed glucocorticoid therapy, yielding 1% prevalence. Incidence of glucocorticoid therapy was 2.8/1000 inhabitants/year. Males represented 44%, the mean age was 58 years. The median prednisone-equivalent dose was 11 mg/day (IQR 9–18 mg/day). 8% underwent bone mass measurement. Calcium and/or vitamin D, and bisphosphonates were prescribed in 18% and 12%, respectively. Results were lower for the control population: 3% underwent bone mass measurement and 3% received bisphosphonate therapy. The rates of osteodensitometry and treatments were higher in women over 55 years of age than in men and women 55 years of age and younger, and also when glucocorticoid therapy was initiated by a rheumatologist versus other physician specialty. Conclusions The management of GIOP remains very inadequate, despite the availability of a statutory health insurance system. Targeted interventions are needed to improve the management of GIOP.

Publications scientifiques (7) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche